Cargando…

Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors

Background: Primary or recurrent head and neck cancer of skin or mucosa represents a challenge for clinicians and could be debilitating for the patient. Electrochemotherapy (ECT) emerged as a local ablative procedure for cutaneous and mucosal head and neck tumors. The aim of this observational study...

Descripción completa

Detalles Bibliográficos
Autores principales: Riva, Giuseppe, Salonia, Laura, Fassone, Elisabetta, Sapino, Silvia, Piano, Fabrizio, Pecorari, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509577/
https://www.ncbi.nlm.nih.gov/pubmed/34640382
http://dx.doi.org/10.3390/jcm10194366
_version_ 1784582375964934144
author Riva, Giuseppe
Salonia, Laura
Fassone, Elisabetta
Sapino, Silvia
Piano, Fabrizio
Pecorari, Giancarlo
author_facet Riva, Giuseppe
Salonia, Laura
Fassone, Elisabetta
Sapino, Silvia
Piano, Fabrizio
Pecorari, Giancarlo
author_sort Riva, Giuseppe
collection PubMed
description Background: Primary or recurrent head and neck cancer of skin or mucosa represents a challenge for clinicians and could be debilitating for the patient. Electrochemotherapy (ECT) emerged as a local ablative procedure for cutaneous and mucosal head and neck tumors. The aim of this observational study was the evaluation of quality of life (QoL) after ECT in patients without other surgical or radiation options as curative treatment. Materials and methods: The procedure was performed according the ESOPE (European Standard Operating procedure of Electrochemotherapy) protocol. Twenty-seven patients were evaluated before ECT (T0) and 1 (T1), 3 (T2), and 6 (T3) months after the procedure. QoL was assessed by means of the EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires. Results: The objective tumor response rate was 48% (11% CR, 37% PR). Bleeding control was achieved in 7/7 patients who experienced bleeding prior to ECT. QoL improvement was observed after the procedure. In particular, global health status and social functioning were higher after ECT (p 0.026 and 0.043), while pain, pain-killers use and appetite loss decreased (p 0.045, 0.025 and 0.002). Conclusion: ECT represents a safe and effective treatment for skin and mucosal head and neck tumors without other curative options. It ensures a good pain and bleeding control without worsening of QoL.
format Online
Article
Text
id pubmed-8509577
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85095772021-10-13 Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors Riva, Giuseppe Salonia, Laura Fassone, Elisabetta Sapino, Silvia Piano, Fabrizio Pecorari, Giancarlo J Clin Med Article Background: Primary or recurrent head and neck cancer of skin or mucosa represents a challenge for clinicians and could be debilitating for the patient. Electrochemotherapy (ECT) emerged as a local ablative procedure for cutaneous and mucosal head and neck tumors. The aim of this observational study was the evaluation of quality of life (QoL) after ECT in patients without other surgical or radiation options as curative treatment. Materials and methods: The procedure was performed according the ESOPE (European Standard Operating procedure of Electrochemotherapy) protocol. Twenty-seven patients were evaluated before ECT (T0) and 1 (T1), 3 (T2), and 6 (T3) months after the procedure. QoL was assessed by means of the EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires. Results: The objective tumor response rate was 48% (11% CR, 37% PR). Bleeding control was achieved in 7/7 patients who experienced bleeding prior to ECT. QoL improvement was observed after the procedure. In particular, global health status and social functioning were higher after ECT (p 0.026 and 0.043), while pain, pain-killers use and appetite loss decreased (p 0.045, 0.025 and 0.002). Conclusion: ECT represents a safe and effective treatment for skin and mucosal head and neck tumors without other curative options. It ensures a good pain and bleeding control without worsening of QoL. MDPI 2021-09-24 /pmc/articles/PMC8509577/ /pubmed/34640382 http://dx.doi.org/10.3390/jcm10194366 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Riva, Giuseppe
Salonia, Laura
Fassone, Elisabetta
Sapino, Silvia
Piano, Fabrizio
Pecorari, Giancarlo
Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors
title Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors
title_full Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors
title_fullStr Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors
title_full_unstemmed Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors
title_short Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors
title_sort quality of life in electrochemotherapy for cutaneous and mucosal head and neck tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509577/
https://www.ncbi.nlm.nih.gov/pubmed/34640382
http://dx.doi.org/10.3390/jcm10194366
work_keys_str_mv AT rivagiuseppe qualityoflifeinelectrochemotherapyforcutaneousandmucosalheadandnecktumors
AT salonialaura qualityoflifeinelectrochemotherapyforcutaneousandmucosalheadandnecktumors
AT fassoneelisabetta qualityoflifeinelectrochemotherapyforcutaneousandmucosalheadandnecktumors
AT sapinosilvia qualityoflifeinelectrochemotherapyforcutaneousandmucosalheadandnecktumors
AT pianofabrizio qualityoflifeinelectrochemotherapyforcutaneousandmucosalheadandnecktumors
AT pecorarigiancarlo qualityoflifeinelectrochemotherapyforcutaneousandmucosalheadandnecktumors